)
)
)
TenaRx
TenaRx, a subsidiary of Biosplice Therapeutics, is building a new therapeutic class around selective inhibition of the CLK and DYRK kinase families—central regulators of cell fate, immune signaling, metabolism, and neurodevelopment. These pathways represent high-value nodes across oncology, metabolic disease, neurodegeneration, and other major indications.
Address
San DiegoCalifornia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)